SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/148980"
 

Search: onr:"swepub:oai:gup.ub.gu.se/148980" > Efficacy in asthma ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Woodcock, Ashley (author)

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial

  • Article/chapterEnglish2011

Publisher, publication year, extent ...

  • 2011-12-01
  • Springer Science and Business Media LLC,2011
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/148980
  • https://gup.ub.gu.se/publication/148980URI
  • https://doi.org/10.1186/1465-9921-12-132DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Abstract Background Fluticasone furoate (FF) is a novel long-acting inhaled corticosteroid (ICS). This double-blind, placebo-controlled randomized study evaluated the efficacy and safety of FF 200 mcg or 400 mcg once daily, either in the morning or in the evening, and FF 200 mcg twice daily (morning and evening), for 8 weeks in patients with persistent asthma. Methods Asthma patients maintained on ICS for ≥ 3 months with baseline morning forced expiratory volume in one second (FEV1) 50-80% of predicted normal value and FEV1 reversibility of ≥ 12% and ≥ 200 ml were eligible. The primary endpoint was mean change from baseline FEV1 at week 8 in pre-dose (morning or evening [depending on regimen], pre-rescue bronchodilator) FEV1. Results A total of 545 patients received one of five FF treatment groups and 101 patients received placebo (intent-to-treat population). Each of the five FF treatment groups produced a statistically significant improvement in pre-dose FEV1 compared with placebo (p < 0.05). FF 400 mcg once daily in the evening and FF 200 mcg twice daily produced similar placebo-adjusted improvements in evening pre-dose FEV1 at week 8 (240 ml vs. 235 ml). FF 400 mcg once daily in the morning, although effective, resulted in a smaller improvement in morning pre-dose FEV1 than FF 200 mcg twice daily at week 8 (315 ml vs. 202 ml). The incidence of oral candidiasis was low (0-4%) and UC excretion was comparable with placebo for all FF groups. Conclusions FF at total daily doses of 200 mcg or 400 mcg was significantly more effective than placebo. FF 400 mcg once daily in the evening had similar efficacy to FF 200 mcg twice daily and all FF regimens had a safety tolerability profile generally similar to placebo. This indicates that inhaled FF is an effective and well tolerated once-daily treatment for mild-to-moderate asthma. Trial registration NCT00398645

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bateman, Eric D (author)
  • Busse, William W (author)
  • Lötvall, Jan,1956Gothenburg University,Göteborgs universitet,Krefting Research Centre(Swepub:gu)xlotja (author)
  • Snowise, Neil G (author)
  • Forth, Richard (author)
  • Jacques, Loretta (author)
  • Haumann, Brett (author)
  • Bleecker, Eugene R (author)
  • Göteborgs universitetKrefting Research Centre (creator_code:org_t)

Related titles

  • In:Respiratory Research: Springer Science and Business Media LLC121465-99211465-993X

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view